COCOON Trial Shows Proactive Skin Care Can Halve Dermatologic Toxicity in EGFR-Mutant NSCLC
News, Oncoscience, Trending
April 3, 2026“Compared to standard reactive care, this strategy halved the incidence of grade ≥2 dermatologic AEs (38.6% vs. 76.5%) and reduced grade ≥3 events and treatment discontinuations.”
BUFFALO, NY — April 3, 2026 — A new research perspective was published in Volume 13 of Oncoscience on March 11, 2026, titled “Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC.”
Led by first and corresponding author Bishal Tiwari from the Nassau University Medical Center and Asmita Koirala from the Western Regional Hospital in Nepal, the commentary summarizes interim findings from the phase II COCOON trial, which tested whether a structured dermatologic prophylaxis regimen could reduce skin toxicities in patients receiving first-line amivantamab plus lazertinib.
The commentary describes a prophylactic protocol that included oral doxycycline or minocycline, ceramide-based moisturization, chlorhexidine nail care, and topical clindamycin. In the interim analysis, the COCOON regimen reduced moderate-to-severe dermatologic adverse events, with the incidence of grade ≥2 events falling from 76.5% with standard reactive care to 38.6% with prophylaxis. The paper also reports reductions in grade ≥3 events and treatment discontinuations, underscoring the practical value of proactive supportive care for EGFR-mutant non-small cell lung cancer.
“The COCOON results emphasize the clinical value of anticipating EGFR inhibitor-related toxicities through multidisciplinary supportive care.”
The authors conclude that these results reinforce the need to integrate dermatologic prevention into first-line treatment planning for EGFR-mutant NSCLC. They note that straightforward, low-cost interventions can improve tolerability and maintain dose intensity, while future clinical practice updates will likely incorporate this kind of proactive supportive care approach more broadly.
DOI: https://doi.org/10.18632/oncoscience.648
Correspondence to: Bishal Tiwari – btiwari@numc.edu
Keywords: cancer, EGFR-mutant non-small cell lung cancer, amivantamab, lazertinib, dermatologic adverse events, COCOON trial
Click here to sign up for free Altmetric alerts about this article.
About Oncoscience:
Oncoscienceis a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: freeing oncology from publication costs. It is free to readers and authors.
Oncoscience is indexed and archived by PubMed, PubMed Central, Scopus, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
For media inquiries, please contact media@impactjournals.com.
